



PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

September 10, 2018

The meeting was called to order by Curtis Gingrich, M.D. at approximately 8:30 a.m. on Monday September 10, 2018.

Committee members present: Curtis Gingrich, M.D.; Kindra Engle, D.O.; Jessica Thurman, P.A.-C; Kim Rothermel, M.D.; Corey Coffey, R.Ph.; Joshua Cox, R.Ph.; Robert Giacalone, and Robert Zaayer, P.A.-C

Staff members present: Sallie Debolt, and Cathy Hacker.

I. Review of the June 12, 2018 minutes:

Dr. Rothermel moved to approve the minutes Ms. Thurman seconded the motion.

All members voted aye. The motion carried.

II. Formulary Review

Ms. Debolt informed the committee that the memo from Westside Medicine did not need to be discussed.

The committee discussed the request from Dr. Hord requesting that Hydroxyurea be listed as CTP may prescribe. The committee recommended leaving it as CTP may not prescribe due to significant side effects.

Dr. Rothermel moved to leave Hydroxyurea as a CTP may not prescribe. Mr. Cox seconded the motion all member voted aye. The motion carried.

The committee discussed Jordan Bulcher's request for antimigraine medications clarification. The antimigraine medications were moved under miscellaneous CNS agents as may prescribe.

Dr. Rothermel moved to approve this change. Mr. Cox seconded the motion. All members voted aye. The motion carried.

The committee then reviewed the new drugs to the market for April -May 2018 as follows:

Tavalisse was all placed under the anti-hemorrhagic agent category as in the PI by protocol category.

Dr. Engle moved to approve this change. Ms. Thurman seconded the motion. All members voted aye. The motion carried.

Crysvita was put into the CTP May not prescribe category.

Dr. Engle moved to approve this change. Dr. Rothermel seconded the motion. All members voted aye. The motion carried.

Akynzeo was put into the CTP may prescribe category under GI Drugs.

Mr. Cox moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

Plenvu and Retacrit are already on the formulary as CRP may prescribe. No changes were made.

Lucemyra was moved to the CTP may prescribe category under miscellaneous CNS Agents.

Ms. Thurman moved to approve this change. Dr. Engle seconded the motion. All members voted aye. The motion carried.

Aimovig and Lokelma are already on the formulary as CTP may prescribe. No change was needed.

Doptelet is already on the formulary as PI by protocol in a hematology oncology setting. No changes needed.

The committee asked that the remainder of the medications be brought to the December meeting.

III. New business

No new business was discussed.

The Physician Assistant Policy Committee meeting was adjourned by Dr. Gingrich at approximately 9:55 a.m. on Monday September 10, 2018.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on September 10, 2018.

Curtis Gingrich, M.D., Chair, PAPC